GSK’s first lung cancer approval, a new IPO path and more

This week on "The Top Line," Fierce Healthcare and Life Sciences' editor-in-chief steps behind the microphone for a solo episode highlighting several of the biggest stories in biopharma.

The episode covers GSK’s first lung cancer approval following its acquisition of Nuvalent, Axiom Biosciences’ unusual plan to list first in Hong Kong before pursuing a Nasdaq co-listing amid a resurgent biotech IPO market, and the U.S. House’s passage of legislation directing the FDA to update its animal testing rules.

The episode also includes an update from the Fierce newsroom, including the arrival of a new Fierce Biotech staff writer, and a reflection on why human judgment, curiosity and original reporting matter more than ever.

To learn more about the topics in this episode: 

• GSK secures first lung cancer approval as FDA clears Jideytro in quick payoff from Nuvalent deal
• ‘There is always a first’: Why US biotech Axiom will begin its IPO journey in Hong Kong
• House passes bill directing FDA to update animal testing rules

See omnystudio.com/listener for privacy information.